Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Stella

Home/Chronic Lymphocytic Leukemia (CLL)/

View on ClinicalTrials.gov

Recruiting

Back to Chronic Lymphocytic Leukemia (CLL) trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Very early testing

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment target

~30 participants

Started

March 2026

Primary completion

February 2030

Age range

18 Years – 100 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.